236 related articles for article (PubMed ID: 18818710)
21. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
22. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
[TBL] [Abstract][Full Text] [Related]
23. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
24. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Danielsson A; Dzojic H; Nilsson B; Essand M
Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
[TBL] [Abstract][Full Text] [Related]
25. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer.
Chen W; Yan C; Hou J; Pu J; Ouyang J; Wen D
Urol Oncol; 2008; 26(4):397-405. PubMed ID: 18367126
[TBL] [Abstract][Full Text] [Related]
26. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
27. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
28. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO
Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843
[TBL] [Abstract][Full Text] [Related]
29. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy.
Wei N; Fan JK; Gu JF; He LF; Tang WH; Cao X; Liu XY
Biochem Biophys Res Commun; 2009 Oct; 388(2):234-9. PubMed ID: 19653996
[TBL] [Abstract][Full Text] [Related]
30. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
31. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
32. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y
Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472
[TBL] [Abstract][Full Text] [Related]
33. [Effect of adenovirus-mediated TK/GCV gene therapy in combination with TNF-alpha against murine bladder cancer cells in vitro].
Shi XH; Tan WL; Zhu WH; Liang ZK; DU YJ
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):750-3. PubMed ID: 18504196
[TBL] [Abstract][Full Text] [Related]
34. Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus.
Hamada K; Zhang T; Desaki J; Nakashiro K; Itoh H; Tani K; Koyama Y; Hamakawa H
J Gene Med; 2010 Jun; 12(6):545-54. PubMed ID: 20527047
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
36. Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene.
Shan YF; Fang YF; Wang XQ; Jin R; Zhang QY; Andersson R
Pancreatology; 2013; 13(4):393-400. PubMed ID: 23890138
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.
Liu C; Sun B; An N; Tan W; Cao L; Luo X; Yu Y; Feng F; Li B; Wu M; Su C; Jiang X
Mol Oncol; 2011 Dec; 5(6):545-54. PubMed ID: 22032823
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
[TBL] [Abstract][Full Text] [Related]
40. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
